US006627196B1

(12) **United States Patent**
Baughman et al.

(10) **Patent No.: US 6,627,196 B1**
(45) **Date of Patent: Sep. 30, 2003**

(54) **DOSAGES FOR TREATMENT WITH ANTI-ERBB2 ANTIBODIES**

(75) Inventors: **Sharon A. Baughman**, Ventura, CA (US); **Steven Shak**, Burlingame, CA (US)

(73) Assignee: **Genentech, Inc.**, South San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/648,067**

(22) Filed: **Aug. 25, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/213,822, filed on Jun. 23, 2000, and provisional application No. 60/151,018, filed on Aug. 27, 1999.

(51) **Int. Cl.**[7] **A61K 39/395**

(52) **U.S. Cl.** **424/138.1**; 424/131.1; 424/133.1; 424/134.1; 424/135.1; 424/136.1; 424/137.1; 424/139.1; 424/141.1; 424/142.1; 424/143.1; 424/144.1; 424/145.1; 424/146.1; 424/147.1; 424/150.1; 424/151.1; 424/152.1; 424/153.1; 424/154.1; 424/155.1; 424/156.1; 424/158.1; 424/172.1; 424/174.1

(58) **Field of Search** 424/130.1, 138.1, 424/141.1, 142.1, 152.1, 155.1, 131.1, 133.1, 134.1, 135.1, 136.1, 137.1, 139.1, 143.1, 144.1, 145.1, 146.1, 147.1, 150.1, 151.1, 153.1, 154.1, 156.1, 158.1, 172.1, 174.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,676,980 A	6/1987	Segal et al.	
4,753,894 A	6/1988	Frankel et al.	
4,816,567 A	3/1989	Cabilly et al.	
4,935,341 A	6/1990	Bargmann et al.	
4,943,533 A	7/1990	Mendelsohn et al.	
4,968,603 A	11/1990	Slamon et al.	
4,975,278 A	12/1990	Senter et al.	
5,169,774 A	12/1992	Frankel et al.	
5,183,884 A	2/1993	Kraus et al.	
5,288,477 A	2/1994	Bacus	
5,359,046 A	10/1994	Capon et al.	
5,367,060 A	11/1994	Vandlen et al.	
5,401,638 A	3/1995	Carney et al.	
5,464,751 A	11/1995	Greene et al.	
5,480,968 A	1/1996	Kraus et al.	
5,578,482 A	11/1996	Lippman et al.	
5,604,107 A	2/1997	Carney et al.	
5,641,869 A	6/1997	Vandlen et al.	
5,663,144 A	9/1997	Greene et al.	
5,677,171 A	10/1997	Hudziak et al.	
5,705,157 A	1/1998	Greene	
5,720,937 A	2/1998	Hudziak et al.	
5,720,954 A	2/1998	Hudziak et al.	
5,725,856 A	3/1998	Hudziak et al.	
5,726,023 A	3/1998	Cheever et al.	
5,728,687 A	3/1998	Bissery	
5,747,261 A	5/1998	King et al.	
5,770,195 A	6/1998	Hudziak et al.	
5,772,997 A	6/1998	Hudziak et al.	
5,776,427 A	7/1998	Thorpe et al.	
5,783,186 A	7/1998	Arakawa et al.	
5,801,005 A	9/1998	Cheever et al.	
5,821,337 A	10/1998	Carter et al.	
5,824,311 A	10/1998	Greene et al.	
5,834,229 A	11/1998	Vandlen et al.	
5,837,243 A	11/1998	Deo et al.	
5,837,523 A	11/1998	Greene et al.	
5,840,525 A	11/1998	Vandlen et al.	
5,846,538 A	12/1998	Cheever et al.	
5,856,110 A	1/1999	Vandlen et al.	
5,859,206 A	1/1999	Vandlen et al.	
5,869,445 A	2/1999	Cheever et al.	
5,876,712 A	3/1999	Cheever et al.	
5,877,305 A	3/1999	Huston et al.	
5,908,835 A	6/1999	Bissery	
5,910,486 A	6/1999	Curiel et al.	
5,922,845 A	7/1999	Deo et al.	
5,939,531 A	8/1999	Wels et al.	
5,968,511 A	10/1999	Akita et al.	
5,977,322 A	11/1999	Marks et al.	
5,985,553 A	11/1999	King et al.	
6,015,567 A	1/2000	Hudziak et al.	
6,028,059 A	2/2000	Curiel et al.	
6,054,297 A	4/2000	Carter et al.	
6,054,561 A	4/2000	Ring	
6,096,873 A	8/2000	Schaefer et al.	
6,123,939 A	9/2000	Shawver et al.	
6,165,464 A	12/2000	Hudziak et al.	
6,333,348 B1 *	12/2001	Vogel et al.	514/449

FOREIGN PATENT DOCUMENTS

EP	0003089 A1	7/1979
EP	0599274 A1	6/1994
EP	616812 A1	9/1994
EP	0711565 B1	8/1998
JP	3-240498	10/1991
JP	5-117165	5/1993
JP	5-170667	7/1993
JP	5-213775	8/1993
JP	5-317084	12/1993
JP	95006982 B2	1/1995
JP	7-59588	3/1995
JP	2761543 B2	6/1998
JP	2895105 B2	5/1999

(List continued on next page.)

OTHER PUBLICATIONS

Wantanabe et al., ASCO, Vol. 17, abstract 702, May 15–18, 1998 Annual Meeting.*

(List continued on next page.)

Primary Examiner—Anthony C. Caputa
Assistant Examiner—Anne L. Holleran
(74) *Attorney, Agent, or Firm*—Wendy M. Lee

(57) **ABSTRACT**

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.

33 Claims, 5 Drawing Sheets